Overview

A Phase 3 Study of NTLA-2001 in ATTRv-PN

Status:
RECRUITING

Trial end date:
2028-08-01

Target enrollment:

Participant gender:

Summary

This study will be conducted to evaluate the efficacy and safety of a single dose of nexiguran ziclumeran (NTLA-2001) compared to placebo in participants with ATTRv-PN.

Phase:

PHASE3

Details

Lead Sponsor:

Intellia Therapeutics

Collaborator:

Regeneron Pharmaceuticals

Treatments:

NTLA-2001
Saline Solution